RT Book, Section
A1 High, Whitney A.
A1 Fitzpatrick, James E.
A2 Goldsmith, Lowell A.
A2 Katz, Stephen I.
A2 Gilchrest, Barbara A.
A2 Paller, Amy S.
A2 Leffell, David J.
A2 Wolff, Klaus
SR Print(0)
ID 56099314
T1 Chapter 227. Cytotoxic and Antimetabolic Agents
T2 Fitzpatrick's Dermatology in General Medicine, 8e
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-166904-7
LK accessmedicine.mhmedical.com/content.aspx?aid=56099314
RD 2024/04/23
AB |PrintCytotoxic  and  Antimetabolic  Agents  at  a  GlanceCytotoxic  and  antimetabolic  agents  are  used  in  dermatology  to  treat  serious,  life-threatening,  and  recalcitrant  disease.Common  agents  used  in  dermatology  include  methotrexate,  azathioprine,  mycophenolate  mofetil,  thioguanine,  hydroxyurea,  cyclophosphamide,  chlorambucil,  and  liposomal  doxorubicin.Methotrexate  is  US  Food  and  Drug  Administration  (FDA)  approved  for  treatment  of  psoriasis  and  advanced  mycosis  fungoides,  whereas  cyclophosphamide  is  FDA  approved  for  advanced  mycosis  fungoides  only,  and  liposomal  doxorubicin  is  approved  for  acquired  immunodeficiency  syndrome-related  Kaposi  sarcoma;  other  uses  of  the  agent  in  this  chapter  occur  on  an  “off-label”  basis.Cytotoxic  and  antimetabolic  agents  act  through  inhibition  and/or  interruption  of  the  cell  cycle.Side  effects  and  complications  with  these  potentially  dangerous  medications  are  numerous,  and  close  clinical  follow-up  and  laboratory  evaluation  is  necessary.Cytotoxic  agents  used  in  dermatology,  as  well  as  those  initiated  for  other  purposes,  may  yield  distinctive  cutaneous  eruptions  and  cutaneous  sequelae.